Company Information
- Type:
- Company
- Country:
- United Kingdom
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 08 January 2010 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Financial Information
Engagements
Affiliated Subsidiaries
Country | Company Name |
---|---|
Mexico | AstraZeneca México |
Sweden | AstraZeneca AB |
Malaysia | AstraZeneca Sdn. Bhd. |
Egypt | AstraZeneca Egypt |
Saudi Arabia | AstraZeneca |
Communication On Progress
Published On | Title | Level/Status |
---|---|---|
27-Jul-2024 | 2024 Communication on Progress | Submitted |
27-Dec-2023 | 2023 Communication on Progress | Submitted |
18-Jul-2022 | 2022 Communication on Progress | Submitted |
27-Jun-2022 | Communication on Progress | Advanced |
31-Mar-2021 | Communication on Progress 2020 | Advanced |
03-Apr-2020 | Communication on Progress | Advanced |
04-Apr-2019 | Communication on Progress AstraZeneca 2019 | Advanced |
23-Apr-2018 | Communication on Progress | Advanced |
29-Apr-2017 | Communication on Progress | Active |
06-Jun-2016 | Communication on Progress AstraZeneca 2016 | Active |
10-Jun-2015 | AstraZeneca Communication on Progress 2015 | Learner |
06-Mar-2015 | Grace Letter | Not applicable |
28-Mar-2014 | Communication on Progress 2014 | Advanced |
28-Mar-2013 | AstraZeneca 2012 | Advanced |
28-Mar-2012 | 2011 Communication on Progress | Advanced |
08-Apr-2011 | 2010 Communication on Progress | Advanced |
21-Dec-2010 | Grace Letter | Not applicable |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.